← All trials
NCT03781115
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 20, 2017
- Primary completion
- Dec 31, 2019
- Completion date
- Jul 31, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 24
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of ArizonaLead sponsor
- University of ArizonaOverall official - principal investigator
- Sidney R. Baer, Jr. FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.